In Deal with Pfizer, Athersys Will Employ Gene Expression Technology to Provide Human Cell Lines | GenomeWeb

NEW YORK, Dec. 13 — Athersys has struck a deal with Pfizer to provide human cell lines that express protein drug targets, the company said Thursday. By the terms of the deal, Athersys will receive licensing fees for each validated line it delivers, milestone payments on candidate therapeutics, and royalties on any products developed.

The Pfizer deal is the fourth collaboration that Athersys has arranged for its RAGE platform, a gene expression system that produces proteins from human genes without cloning or cDNA libraries.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.